<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094717</url>
  </required_header>
  <id_info>
    <org_study_id>IRB_00031865</org_study_id>
    <nct_id>NCT01094717</nct_id>
  </id_info>
  <brief_title>Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis</brief_title>
  <official_title>A Comparison of Treatment of Psoriasis With Acitretin or Tazarotene Gel 0.1% and Active or Sham Treatments With the 308 nm Excimer Laser</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind study of excimer (308-nm UVB) laser added to either
      tazarotene 0.1% gel or acitretin 25 mg daily for plaque psoriasis.

      The primary objective of this study is to compare the improvement of psoriatic plaques with
      and without excimer laser (308-nm UVB) treatment, applied in a randomized and blinded
      fashion, in subjects on acitretin 25 mg or tazarotene gel 0.1% QD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis of this study is that excimer (308-nm UVB) laser added to either tazarotene
      0.1% gel or acitretin 25 mg daily will lead to improved efficacy of these treatments alone.

      The primary objective of this study is to compare the improvement of psoriatic plaques with
      and without excimer laser (308-nm UVB) treatment, applied in a randomized and blinded
      fashion, in subjects on acitretin 25 mg or tazarotene gel 0.1% QD. The primary endpoint will
      be the comparison between the change in NPF score of plaques treated with excimer laser and
      those treated with sham treatment.

      The secondary objectives are to compare the number of excimer light treatments and time
      necessary to achieve an average lesion assessment score of 0 to 1 in subjects treated with
      acitretin 25 mg PO or tazarotene gel 0.1% QD, and to evaluate adverse events related to
      combinations of the study treatments.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of efficacy and lack of funding
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Excimer laser active and comparator were delivered the same way by a non-blinded person who applies a cap to the laser head to block UV rays for a sham administration. The masking was done by blindfolding the patients so they could not see which side was treated with active or sham laser. The outcomes assessor did their assessment in a separate room and access restricted to the randomization assignments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the NPF Psoriasis Score of Plaques</measure>
    <time_frame>week 8</time_frame>
    <description>mean % change in the National Psoriasis Foundation (NPF) psoriasis score of the target plaques [higher percent change in NPF score is consistent with improvement, while higher absolute NPF score is consistent with worse disease, minimum score of 0 (no disease) and maximum score of 30 (worst disease)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Achieved an Average Lesion Assessment Score of 0 or 1 at Week 12.</measure>
    <time_frame>8 weeks</time_frame>
    <description>number of patients who achieved average lesion assessment score of 0 or 1 by the Target Plaque Sum Score (TPSS) for each arm/intervention. For the TPSS, the target plaque was assessed separately for induration, scaling, and erythema using a 6-point severity scale (0 = none and 5 = severe) and the scores were summed to produce the Target Plaque Sum Score [15-point scale; maximum (most severe) score 15].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>We will collect number and types of adverse events for the excimer-treated vs. sham-treated sites</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>acitretin and active excimer laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients enrolled in the acitretin arm will be treated with acitretin 25 mg daily and excimer (active) to randomly assigned left or right side of body psoriasis lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acitretin and sham excimer laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm were treated with acitretin 25 mg daily and sham (placebo) excimer laser to randomly assigned left or right side of body psoriasis lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tazarotene and active excimer laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients enrolled in this arm were treated with tazarotene 0.1% gel topical application daily and excimer (active) laser to randomly assigned left or right side of body psoriasis lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tazarotene and sham excimer laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients enrolled in this arm were treated with tazarotene 0.1% gel topical application daily and sham excimer laser to randomly assigned left or right side of body psoriasis lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acitretin 25Mg Oral Capsule</intervention_name>
    <description>Acitretin 25 mg oral daily for 12 weeks</description>
    <arm_group_label>acitretin and active excimer laser</arm_group_label>
    <arm_group_label>acitretin and sham excimer laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Excimer laser</intervention_name>
    <description>Lesions on randomly assigned left or right side of body were treated with 308nm excimer laser.</description>
    <arm_group_label>acitretin and active excimer laser</arm_group_label>
    <arm_group_label>tazarotene and active excimer laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazarotene 0.1% Gel,Top</intervention_name>
    <description>Topical tazarotene 0.1% gel was applied daily to active lesions.</description>
    <arm_group_label>tazarotene and active excimer laser</arm_group_label>
    <arm_group_label>tazarotene and sham excimer laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham excimer laser</intervention_name>
    <description>Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).</description>
    <arm_group_label>acitretin and sham excimer laser</arm_group_label>
    <arm_group_label>tazarotene and sham excimer laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must give written informed consent

          -  Must be at least 18 years old

          -  Must have been diagnosed with stable plaque type psoriasis covering between 1 and 5%
             BSA

          -  NPF-PS â‰¥8 (based additive scores averaged over all lesions for erythema, scale, and
             thickness range of score = 0-5)

          -  No systemic or phototherapy in the 4 wks prior to entering the study

          -  No topical therapy other than emollients (no corticosteroids, vitamin D analogs,
             vitamin A analogs) in the 2 wks prior to entering the study

          -  Women on tazarotene gel must not be pregnant nor planning to become pregnant during
             the study and must be on two forms of birth control

          -  Subjects known to not tolerate oral acitretin at 25 mg/day and women of child-bearing
             potential may be enrolled and treated with topical tazarotene gel 0.1%

        Exclusion Criteria:

        Candidates will be excluded from study entry if any of the following exclusion criteria
        exist at the time of enrollment:

          -  Unstable disease

          -  Only treatable sites are in intertriginous areas or on face

          -  Subjects unable to tolerate frequency of visits

          -  NPF-PS severity score &lt;8 additive score of erythema, scale, and thickness, averaged
             over all lesions

          -  History of inability to tolerate topical tazarotene 0.1% gel and or acitretin 25
             mg/day

          -  Women of childbearing potential are excluded from the actretin arm of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina C Duffin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah Department of Dermatology</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 25, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2010</study_first_posted>
  <results_first_submitted>October 3, 2016</results_first_submitted>
  <results_first_submitted_qc>June 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 26, 2019</results_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Kristina Callis</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>excimer</keyword>
  <keyword>acitretin</keyword>
  <keyword>tazarotene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazarotene</mesh_term>
    <mesh_term>Acitretin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acitretin and Excimer</title>
          <description>Patients treated with acitretin 25 mg daily and active excimer laser to lesions on one half of the body (side assigned to active laser) and sham excimer laser (opaque cover on laser lens)to lesions on the other half of the body (side assigned to sham laser).</description>
        </group>
        <group group_id="P2">
          <title>Tazarotene Gel and Excimer Laser</title>
          <description>patients in this group applied tazarotene 0.1% gel to all lesions and active excimer laser used to treat lesions on one half of the body (side assigned to active laser) and sham excimer laser (opaque cover applied over laser lens) used to treat lesions on the other half of the body (side assigned to sham laser).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acitretin and Excimer</title>
          <description>excimer vs sham excimer: half of lesions will be treated with excimer laser; half of lesions will be treated with sham excimer (opaque cover on the laser device)</description>
        </group>
        <group group_id="B2">
          <title>Tazarotene and Excimer</title>
          <description>excimer vs sham excimer: half of lesions will be treated with excimer laser; half of lesions will be treated with sham excimer (opaque cover on the laser device)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.6" spread="19.4"/>
                    <measurement group_id="B2" value="46.4" spread="17.2"/>
                    <measurement group_id="B3" value="46.6" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the NPF Psoriasis Score of Plaques</title>
        <description>mean % change in the National Psoriasis Foundation (NPF) psoriasis score of the target plaques [higher percent change in NPF score is consistent with improvement, while higher absolute NPF score is consistent with worse disease, minimum score of 0 (no disease) and maximum score of 30 (worst disease)]</description>
        <time_frame>week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acitretin and Excimer</title>
            <description>patients received acitretin 25 mg daily and active excimer laser excimer twice weekly to lesions on one of half of the body that was assigned to active laser (left or right determined by randomization)</description>
          </group>
          <group group_id="O2">
            <title>Acitretin and Sham (Placebo) Excimer</title>
            <description>patients received acitretin 25 mg daily and sham (placebo) excimer twice weekly to lesions on one of half of the body that was assigned to sham (left or right determined by randomization)</description>
          </group>
          <group group_id="O3">
            <title>Tazarotene Gel and Excimer Laser</title>
            <description>patients received topical tazarotene gel 0.1% applied to all lesions daily, and active excimer laser excimer twice weekly to lesions on one of half of the body that was assigned to active laser (left or right determined by randomization)</description>
          </group>
          <group group_id="O4">
            <title>Tazarotene Gel and Sham (Placebo) Excimer</title>
            <description>patients receive tazarotene gel 0.1% applied daily to all lesions, and sham excimer twice weekly to lesions on one of half of the body that was assigned to sham (left or right determined by randomization)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the NPF Psoriasis Score of Plaques</title>
          <description>mean % change in the National Psoriasis Foundation (NPF) psoriasis score of the target plaques [higher percent change in NPF score is consistent with improvement, while higher absolute NPF score is consistent with worse disease, minimum score of 0 (no disease) and maximum score of 30 (worst disease)]</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.0" spread="26.5"/>
                    <measurement group_id="O2" value="-52.1" spread="36.3"/>
                    <measurement group_id="O3" value="-32.7" spread="10.4"/>
                    <measurement group_id="O4" value="-26.9" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Achieved an Average Lesion Assessment Score of 0 or 1 at Week 12.</title>
        <description>number of patients who achieved average lesion assessment score of 0 or 1 by the Target Plaque Sum Score (TPSS) for each arm/intervention. For the TPSS, the target plaque was assessed separately for induration, scaling, and erythema using a 6-point severity scale (0 = none and 5 = severe) and the scores were summed to produce the Target Plaque Sum Score [15-point scale; maximum (most severe) score 15].</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acitretin and Excimer</title>
            <description>patients enrolled in the acitretin arm will be treated with acitretin 25 mg daily and excimer (active) to one side of the body and sham excimer (placebo) to the to the other side of body.
excimer vs sham excimer: half of lesions will be treated with excimer laser; half of lesions will be treated with sham excimer (opaque cover on the laser device)</description>
          </group>
          <group group_id="O2">
            <title>Acitretin and Sham Excimer Laser</title>
            <description>patients treated with acitretin 25 mg and sham excimer laser.</description>
          </group>
          <group group_id="O3">
            <title>Tazarotene and Excimer</title>
            <description>patients enrolled in the tazarotene arm will be treated with topical tazarotene 0.1% gel and excimer (active) to one side of the body and sham excimer (placebo) to the to the other side of body.
excimer vs sham excimer: half of lesions will be treated with excimer laser; half of lesions will be treated with sham excimer (opaque cover on the laser device)</description>
          </group>
          <group group_id="O4">
            <title>Tazarotene and Sham Excimer Laser</title>
            <description>patients receiving tazotene gel 0.1% and sham excimer laser to half of body.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Achieved an Average Lesion Assessment Score of 0 or 1 at Week 12.</title>
          <description>number of patients who achieved average lesion assessment score of 0 or 1 by the Target Plaque Sum Score (TPSS) for each arm/intervention. For the TPSS, the target plaque was assessed separately for induration, scaling, and erythema using a 6-point severity scale (0 = none and 5 = severe) and the scores were summed to produce the Target Plaque Sum Score [15-point scale; maximum (most severe) score 15].</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>We will collect number and types of adverse events for the excimer-treated vs. sham-treated sites</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acitretin and Active Excimer Laser</title>
            <description>patients enrolled in the acitretin arm will be treated with acitretin 25 mg daily and excimer (active) to randomly assigned left or right side of body psoriasis lesions.
excimer laser (active): Lesions on randomly assigned left or right side of body were treated with active excimer laser by an increasing dose level per a standard of care protocol.
Acitretin 25 MG: Patients assigned to this intervention took oral acitretin 25 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Acitretin and Sham Excimer Laser</title>
            <description>Patients in this arm were treated with acitretin 25 mg daily and sham (placebo) excimer laser to randomly assigned left or right side of body psoriasis lesions.
excimer laser (sham): Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).
Acitretin 25 MG: Patients assigned to this intervention took oral acitretin 25 mg daily.</description>
          </group>
          <group group_id="O3">
            <title>Tazarotene and Active Excimer Laser</title>
            <description>patients enrolled in this arm were treated with tazarotene 0.1% gel topical application daily and excimer (active) laser to randomly assigned left or right side of body psoriasis lesions.
excimer laser (active): Lesions on randomly assigned left or right side of body were treated with active excimer laser by an increasing dose level per a standard of care protocol.
Tazarotene 0.1% gel: Patients assigned to this intervention applied topical tazarotene gel 0.1% to all lesions daily.</description>
          </group>
          <group group_id="O4">
            <title>Tazarotene and Sham Excimer Laser</title>
            <description>patients enrolled in this arm were treated with tazarotene 0.1% gel topical application daily and sham excimer laser to randomly assigned left or right side of body psoriasis lesions.
excimer laser (sham): Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).
Acitretin 25 MG: Patients assigned to this intervention took oral acitretin 25 mg daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>We will collect number and types of adverse events for the excimer-treated vs. sham-treated sites</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Acitretin and Excimer</title>
          <description>excimer vs sham excimer: half of lesions will be treated with excimer laser; half of lesions will be treated with sham excimer (opaque cover on the laser device)</description>
        </group>
        <group group_id="E2">
          <title>Tazarotene and Excimer</title>
          <description>excimer vs sham excimer: half of lesions will be treated with excimer laser; half of lesions will be treated with sham excimer (opaque cover on the laser device)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated triglycerides</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry lips</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bump on figner</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Inflamed seborrheic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kristina Callis-Duffin</name_or_title>
      <organization>University of Utah, Derpartment of Dermatology</organization>
      <phone>8015816465</phone>
      <email>Kristina.Duffin@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

